N‐acetyltransferase‐2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men
Open Access
- 5 March 2003
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 10 (3) , 167-173
- https://doi.org/10.1046/j.1442-2042.2003.00586.x
Abstract
Background: The purpose of this study was to determine the frequency of a polymorphism of the candidate metabolic enzyme N‐acetyltransferase‐2 (NAT2) in Japanese prostate cancer patients and Japanese non‐cancer controls, in order to determine if an association exists between NAT2 genotype and the occurrence, clinical stage and grade of prostate cancer.Methods: In the present case‐control study, 111 patients with prostate cancer and 152 controls were genotyped for the NAT2 polymorphism using the polymerase chain reaction‐based restriction fragment length polymorphism method. The NAT2 genotypes (slow or rapid acetylator genotype) were determined by the combination of three known NAT2 mutant alleles (M1, M2, M3) and the wild‐type allele.Results: The NAT2 slow acetylator genotype was statistically higher among prostate cancer patients (17.1%) compared with controls (8.6%) (Odds ration (OR) = 2.21; 95% confidence interval (CI), 1.04–4.69; P = 0.0289). In addition, there was a statistically increased risk of prostate cancer among smokers with the NAT2 slow genotype (OR = 3.78: 95% CI, 1.48–9.66; P = 0.0041). Furthermore, the NAT2 slow acetylator genotype was significantly higher among prostate cancer patients with locally advanced and metastatic disease (22.7%) compared with controls (8.6%) (OR = 3.14; 95% CI, 1.40–7.06; P = 0.0051). Lastly, the NAT2 slow acetylator genotype was significantly higher among prostate cancer patients with high‐grade tumors (31.4%) compared with controls (8.6%) (OR = 4.90; 95% CI, 1.97–12.20; P = 0.0010).Conclusion: These data demonstrate that the NAT2 slow acetylator genotype plays an important role in determining the risk of developing prostate cancer in Japanese men and is also associated with more clinically advanced and pathologically aggressive disease. Furthermore, a possible interaction between the NAT2 slow acetylator genotype and smoking status was suggested.Keywords
This publication has 26 references indexed in Scilit:
- Clinical and Pathological Significance of Vitamin D Receptor Gene Polymorphism for Prostate Cancer which Is Associated with a Higher Mortality in Japanese.Endocrine Journal, 2001
- Arylaminc N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among JapanesePharmacogenetics, 1999
- Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populationsPharmacogenetics, 1996
- Cancer genes: single and susceptibility: exposing the differencePharmacogenetics, 1995
- Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) genePharmacogenetics, 1994
- Do Diet and Androgens Alter Prostate Cancer Risk via a Common Etiologic Pathway?JNCI Journal of the National Cancer Institute, 1994
- Carcinogenic factors in food with relevance to colon cancer developmentMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1993
- SHORT COMMUNICATION: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-AmericansCarcinogenesis: Integrative Cancer Research, 1993
- Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variantsPharmacogenetics, 1992
- N-acetyltransferasePharmacology & Therapeutics, 1989